Rigel Pharma (RIGL) Tops Q4 EPS by 2c, Tops on Revenue
Tweet
Share
E-mailGet Alerts RIGL Hot Sheet
Price: $45.80 +1.22%
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Contract revenues from collaborations: 3.76M
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Rigel Pharma (NASDAQ: RIGL) reported Q4 EPS of $0.00, $0.02 better than the analyst estimate of ($0.02). Revenue for the quarter came in at $35.8 million versus the consensus estimate of $34.1 million.
For earnings history and earnings-related data on Rigel Pharma (RIGL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
- ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
